Matthew A Brown

Rare and Common Variants in GALNT3 May Affect Bone Mass Independently of Phosphate Metabolism

E. Grundberg, M. Brandi, E. Duncan, 2023, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

M. Dougados, Huji Xu, A. Deodhar, 2023, Annals of the rheumatic diseases.

Genetically encoded Runx3 and CD4+ intestinal epithelial lymphocyte deficiencies link SKG mouse and human predisposition to spondyloarthropathy.

Ahmed M. Mehdi, F. Ciccia, Ranjeny Thomas, 2022, Clinical immunology.

Reduction of New Heterotopic Ossification (HO) in the Open‐Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP)

E. Hsiao, A. Strahs, R. Pignolo, 2022, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Risk‐mitigating behaviours in people with inflammatory skin and joint disease during the COVID‐19 pandemic differ by treatment type: a cross‐sectional patient survey*

L. Naldi, S. Langan, I. Bruce, 2020, medRxiv.

Inflammasome Activation in Ankylosing Spondylitis Is Associated With Gut Dysbiosis

M. Brown, S. Raimondo, D. Elewaut, 2021, Arthritis & rheumatology.

The Journal of Rheumatology genetic risk score combining 110 SNPs of genome-wide significance Prediction of ankylosing spondylitis in the population-based HUNT study by a

O. Holmen, K. Hveem, M. Hoff, 2019 .